Original Research
Published on 20 Dec 2022
in Immunological Tolerance and Regulation
Original Research
Published on 20 Dec 2022
in Nutritional Immunology
Original Research
Published on 20 Dec 2022
in Viral Immunology
Original Research
Published on 20 Dec 2022
in Inflammation
Correction
Published on 20 Dec 2022
in Cancer Immunity and Immunotherapy
Review
Published on 20 Dec 2022
in Alloimmunity and Transplantation
Original Research
Published on 20 Dec 2022
in Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
Editorial
Published on 20 Dec 2022
in Cancer Immunity and Immunotherapy
Original Research
Published on 20 Dec 2022
in Viral Immunology
Original Research
Published on 20 Dec 2022
in Molecular Innate Immunity
Correction
Published on 20 Dec 2022
in Primary Immunodeficiencies
Original Research
Published on 20 Dec 2022
in Cancer Immunity and Immunotherapy
Original Research
Published on 20 Dec 2022
in Cancer Immunity and Immunotherapy
Original Research
Published on 20 Dec 2022
in Vaccines and Molecular Therapeutics
Mini Review
Published on 20 Dec 2022
in NK and Innate Lymphoid Cell Biology
Original Research
Published on 20 Dec 2022
in Inflammation
![Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the treatment of patients with primary immunodeficiencies](https://www.frontiersin.org/files/myhome article library/1110388/1110388_Thumb_400.jpg)
